Frederic Chereau - 01 Mar 2022 Form 4 Insider Report for LogicBio Therapeutics, Inc.

Role
President and Chief Executive, Director
Signature
/s/ Andrea Paul, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
01 Mar 2022
Net transactions value
$0
Form type
4
Filing time
03 Mar 2022, 16:54:05 UTC
Next filing
17 Nov 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LOGC Stock Option (right to buy) Award $0 +328,000 $0.000000 328,000 01 Mar 2022 Common Stock 328,000 $0.7000 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options were granted by LogicBio Therapeutics, Inc. (the "Company") pursuant to its 2018 Equity Incentive Plan.
F2 The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Company on each vesting date.

Remarks:

Exhibit List: Exhibit 24.1 Power of Attorney